Orthofix Medical Inc. (NASDAQ:OFIX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Orthofix Medical Inc. (NASDAQ:OFIX) have been given an average recommendation of “Moderate Buy” by the five ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $21.75.

Several equities analysts have recently weighed in on OFIX shares. Barrington Research reissued an “outperform” rating and set a $17.00 price target on shares of Orthofix Medical in a report on Tuesday, September 23rd. Wall Street Zen raised Orthofix Medical from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. Finally, JMP Securities reissued a “market perform” rating on shares of Orthofix Medical in a report on Friday, June 6th.

Hedge Funds Weigh In On Orthofix Medical

Several institutional investors have recently made changes to their positions in the business. Paradigm Capital Management Inc. NY raised its holdings in Orthofix Medical by 34.6% in the 2nd quarter. Paradigm Capital Management Inc. NY now owns 3,340,600 shares of the medical device company’s stock worth $37,248,000 after purchasing an additional 858,900 shares during the period. Bank of America Corp DE raised its holdings in Orthofix Medical by 659.5% in the 2nd quarter. Bank of America Corp DE now owns 687,410 shares of the medical device company’s stock worth $7,665,000 after purchasing an additional 596,907 shares during the period. Engine Capital Management LP raised its holdings in Orthofix Medical by 13.6% in the 2nd quarter. Engine Capital Management LP now owns 4,251,671 shares of the medical device company’s stock worth $47,406,000 after purchasing an additional 510,281 shares during the period. AYAL Capital Advisors Ltd raised its holdings in Orthofix Medical by 74.7% in the 2nd quarter. AYAL Capital Advisors Ltd now owns 943,203 shares of the medical device company’s stock worth $10,517,000 after purchasing an additional 403,433 shares during the period. Finally, Philosophy Capital Management LLC bought a new position in shares of Orthofix Medical in the first quarter worth about $6,047,000. Institutional investors own 89.76% of the company’s stock.

Orthofix Medical Trading Up 1.9%

Shares of NASDAQ:OFIX opened at $14.64 on Wednesday. The company has a market cap of $578.13 million, a P/E ratio of -4.62 and a beta of 0.86. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.67 and a quick ratio of 1.50. Orthofix Medical has a 1 year low of $10.24 and a 1 year high of $20.73. The stock’s fifty day moving average price is $13.81 and its 200-day moving average price is $13.05.

Orthofix Medical (NASDAQ:OFIX) last announced its quarterly earnings results on Tuesday, August 5th. The medical device company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.40). The business had revenue of $203.12 million for the quarter, compared to the consensus estimate of $196.89 million. Orthofix Medical had a negative net margin of 15.29% and a negative return on equity of 25.43%. Orthofix Medical has set its FY 2025 guidance at EPS. Sell-side analysts expect that Orthofix Medical will post -2.81 earnings per share for the current year.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.